Post-COVID-19 vývoj chronické zánětlivé demyelinizační polyneuropatie s akutním začátkem léčené rituximabem

Stáhnout PDF English version

Autoři: K. Revendová ^1,2; M. Bar ^1,2; O. Volný ^1,2
Působiště autorů: Department of Clinical Neurosciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic ¹; Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic ²
Vyšlo v časopise: Cesk Slov Neurol N 2022; 85(4): 336-337
Kategorie: Dopisy redakci
doi: https://doi.org/10.48095/cccsnn2022336

Zdroje

1. Van den Bergh PYK, Doorn PA, Hadden RDM et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force –⁠ Second revision. J Peripher Nerv Syst 2021; 26 (3): 242–268. doi: 10.1111/jns.12455.

2. Revendova K, Volny O, Junkerova J et al. Nodo-paranodopatie s protilátkami IgG4 proti neurofascinu-155. Cesk Slov Neurol N 2021; 84/117 (6): 567–569. doi: 10.48095/cccsnn2021567.

3. Oo WM, Giri P, de Souza A. AstraZeneca COVID-19 vaccine and Guillain-Barré Syndrome in Tasmania: a causal link? J Neuroimmunol 2021; 360 : 577719. doi: 10.1016/j.jneuroim.2021.577719.

4. Bagella CF, Corda DG, Zara P et al. Chronic inflammatory demyelinating polyneuropathy after ChAdOx1 nCoV-19 vaccination. Vaccines 2021; 9 (12): 1502. doi: 10.3390/ vaccines9121502.

5. Suri V, Pandey S, Singh J et al. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID--19 infection and subsequent ChAdOx1 nCoV-19 vaccination. BMJ Case Rep 2021; 14 (10): e245816. doi: 10.1136/bcr-2021-245816.

6. Lin J, Gao Q, Xiao K at al. Efficacy of therapies in the treatment of Guillain-Barre syndrome: a network meta-analysis. Medicine 2021; 100 (41): e27351. doi: 10.1097/MD. 0000000000027351.

7. Tang L, Huang Q, Qin Z et al. Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features. J Neurol 2021; 268 (8): 2757–2768. doi: 10.1007/s00415-020-098 23-2.